PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

• J. Koreth,
• L. Kean,
• L. Chinn,
• L. M. Acevedo,
• O. Bandman,
• J. Rothman,
• S. Connelly,
• D. Thomas,
• C. Cutler

Affiliations

J. Koreth

1 Division of Stem Cell Transplantation and Cellular Therapy

L. Kean

2 Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston

L. Chinn

3 Equillium, Inc., La Jolla, United States of America

L. M. Acevedo

3 Equillium, Inc., La Jolla, United States of America

O. Bandman

3 Equillium, Inc., La Jolla, United States of America

J. Rothman

3 Equillium, Inc., La Jolla, United States of America

S. Connelly

3 Equillium, Inc., La Jolla, United States of America

D. Thomas

3 Equillium, Inc., La Jolla, United States of America

C. Cutler

1 Division of Stem Cell Transplantation and Cellular Therapy